

Evonik launches improved L-Ornithine-L-Aspartate formulations

Evonik launches a series of new formulations of L-Ornithine-L-Aspartate (LOLA) at this year's CPhI Worldwide trade show in Madrid.

The new formulations simplify the administration of this important therapeutic agent for liver diseases. The innovations should improve acceptance with patients and should open new markets for pharmaceutical and nutraceutical companies.

LOLA supports the reduction of ammonia concentrations in patients with a damaged liver, a problem globally on the rise. Up to now, the existing delivery forms are injectable or powders. The powders are known to be difficult to prepare and unpleasant to drink.

“Our aim was to increase the acceptance of patients by delivering a product with significantly improved mouthfeel and taste,” explains Dr. Ashish Guha, responsible R&D manager for the new developments. In addition, the company has changed the crystalline structure of the product to speed up disintegration in water and to make the formulation drinkable faster. The new offering consists of effervescent tablets and granules, mouth-dissolving granules, chewable tablets as well as tea bags.

Osama Arabi-Katbi, who is commercially responsible for the new launches, emphasizes, “We have taken the different market needs into account. The formulations can easily and quickly be launched into the market, as we can offer all necessary regulatory approvals.”

Evonik does not only offer the formulation expertise and related intellectual property to customers but also offers LOLA with highest quality standards. Through its backward integration, the company can guarantee supply security.

October 13, 2015

Contact person specialized press
Dr. Jürgen Krauter
Vice President Communications
Phone +49 6181 59-6847
Fax +49 6181 59-76847
juergen.krauter@evonik.com

Contact person specialized press
Hannah Rausche
Head of Communications
Health Care
Phone +49 6151 18-3567
Fax +49 6151 18-72567
hannah.rausche@evonik.com

Evonik Nutrition & Care GmbH
Rellinghauser Straße 1-11
45128 Essen
Telephone +49 201 177-01
Telefax +49 201 177-3475
Germany

www.evonik.com

Supervisory Board
Dr. Ralph Sven Kaufmann,
Chairman
Managing Directors
Dr. Reiner Beste, Chairman
Dr. Hans Josef Ritzert, Michael
Gattermann, Markus Schäfer

Registered Office Essen
Register Court
City Local Court Essen
Commercial Registry B 25784

Given the expected rise in lifestyle related liver diseases, Evonik continues to invest in its line of Ornithine and Arginine based derivatives. In addition to LOLA, the company also offers L-Ornithine α -Ketoglutarate, L-Ornithine HCl, and L-Arginine-L-Aspartate.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around €4.2 billion in 2014.

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.